Biocytogen Launches RenNano™ Mouse, a Fully Human Heavy Chain Antibody Platform to Accelerate Nanobody Drug Discovery
| Date | 3rd, Jan 2023 |
|---|---|
| Source | AZoNano - Nanotechnology Websites |
DESCRIPTION
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. today officially launched its fully human heavy chain antibody platform, RenNano™. RenNano™ is the third member of the RenMice™ family, joining RenMab™ and RenLite®. Together, Biocytogen’s three RenMice™ platforms allow for the streamlined discovery and development of fully human monoclonal antibodies, bispecific/multispecific antibodies and single-domain antibodies (sdAbs, or nanobodies).